Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uveal Melanoma 1 Tuberous Sclerosis 1 Seizures 1 Recurrence 1 Neoplasm Metastasis 1 Melanoma 1 Lennox Gastaut Syndrome 1 Glioblastoma 1 Epilepsies, Myoclonic 1

Interventions

Dexamethasone 18 Cyclophosphamide 16 fludarabine 11 pomalidomide 9 pembrolizumab 9 carfilzomib 9 daratumumab 7 Rituximab 7 Lenalidomide 7 Calcium Dobesilate 7 fludarabine phosphate 6 Gemcitabine 6 Cisplatin 6 Bortezomib 6 venetoclax 5 elotuzumab 4 isatuximab 3 blinatumomab 3 Vincristine 3 Radiotherapy 3 Prednisone 3 Etoposide 3 Doxorubicin 3 Cytarabine 3 tisagenlecleucel 2 selinexor 2 ruxolitinib 2 ixazomib 2 dexamethasone 21-phosphate 2 cabazitaxel 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Recurrence × Solutions × Clear all

NCT03233152 2025-11-21

GlitIpNi

Universitair Ziekenhuis Brussel

Phase 1/2 Active not recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡